BHC logo

Bausch Health Companies Inc. (BHC)

$8.47

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on BHC

Market cap

$3.17B

EPS

-2.29

P/E ratio

--

Price to sales

0.21

Dividend yield

--

Beta

0.306207

Price on BHC

Previous close

$8.42

Today's open

$8.39

Day's range

$8.21 - $8.48

52 week range

$4.33 - $9.04

Profile about BHC

CEO

Thomas J. Appio

Employees

20300

Headquarters

Laval, QC

Exchange

New York Stock Exchange

Shares outstanding

374266716

Issue type

Common Stock

BHC industries and sectors

Healthcare

Pharmaceuticals

News on BHC

Here's Why Bausch Health (BHC) is a Strong Momentum Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

news source

Zacks Investment Research • Nov 12, 2026

news preview

Bausch Health's Gastroenterology Business, Salix, to Present New Data on Cirrhosis Trends and Severe Alcohol-Associated Hepatitis at The Liver Meeting® 2026

LAVAL, QC, Nov. 6, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals, will present a research poster at the American Association for the Study of Liver Diseases' The Liver Meeting® 2026, November 5–9 in Denver, Colorado. The study highlights the substantial mortality and rehospitalization among patients hospitalized with severe alcohol-associated hepatitis (AH).

news source

PRNewsWire • Nov 6, 2026

news preview

BHC Q3 Earnings Call Highlights Raised Outlook, Xifaxan Risks

Bausch Health Companies Inc. BHC emphasized sustained operational growth, stronger cash generation and improved financial flexibility during its third-quarter 2026 earnings call. Management raised its full-year guidance while outlining anticipated headwinds from Xifaxan pricing changes and inventory adjustments.

news source

Zacks Investment Research • Nov 4, 2026

news preview

Is Bausch Health (BHC) Stock Outpacing Its Medical Peers This Year?

Here is how Bausch Health (BHC) and Bausch + Lomb (BLCO) have performed compared to their sector so far this year.

news source

Zacks Investment Research • Nov 3, 2026

news preview

Bausch Health Companies Inc. (BHC) Q3 2026 Earnings Call Transcript

Bausch Health Companies Inc. ( BHC ) Q3 2026 Earnings Call October 28, 2026 5:00 PM EDT Company Participants Garen Sarafian Thomas Appio - CEO & Director Jean-Jacques Charhon - Executive VP & CFO Conference Call Participants Umer Raffat - Evercore ISI Institutional Equities, Research Division Douglas Miehm - RBC Capital Markets, Research Division Presentation Operator Greetings, and welcome to the Bausch Health Third Quarter 2026 Earnings Conference Call. As a reminder, this conference is being recorded.

news source

Seeking Alpha • Oct 29, 2026

news preview

BHC Q3 Earnings Beat on Salix Growth, Stock Gains 9% as Outlook Rises

Bausch Health shares jump 9% as Q3 earnings top estimates, driven by Xifaxan-led Salix growth, improved profitability and raised 2026 guidance.

news source

Zacks Investment Research • Oct 29, 2026

news preview

What Bausch Health Cos (BHC) Said on Its Q3 Earnings Call

Bausch Health Cos NYSE: BHC raised its full-year 2026 outlook for the second consecutive quarter after reporting third-quarter growth across its operating segments, led by Salix and supported by international operations and Solta Medical.

news source

MarketBeat • Oct 29, 2026

news preview

BAUSCH HEALTH ANNOUNCES THIRD QUARTER 2026 RESULTS, RAISES GUIDANCE

Third Quarter Consolidated Revenues of $2.94 billion, up 10% on a Reported basis and 8% on an Organic1 basis over the prior year period GAAP Net Income Attributable to Bausch Health of $436 million and GAAP Net Income of $446 million GAAP Earnings per Diluted Share Attributable to Bausch Health of $1.15 compared to $0.48 in the prior year period; Adjusted Earnings per Diluted Share1 of $1.77 compared to $1.16 in the prior year period, an increase of 53% Consolidated Adjusted EBITDA Attributable to Bausch Health1 of $1,305 million, up 32% over the prior year period BAUSCH HEALTH EXCLUDING BAUSCH + LOMB THIRD QUARTER 2026 RESULTS Delivered fourteenth consecutive quarter of year-over-year Revenue and Adjusted EBITDA1 growth, with 12% Reported and 8% Organic Revenue1 growth and 32% Adjusted EBITDA1 growth Net Income increased $205 million over the prior year Generated $581 million in Cash Provided by Operating Activities and $539 million in Adjusted Cash Flows from Operations1 Raising full year 2026 Revenue, Adjusted EBITDA1, and Adjusted Cash Flows from Operations1 guidance LAVAL, QC, Oct. 28, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company" or "we" or "our") today announced its third quarter 2026 financial results and other key updates from the quarter. "Bausch Health, excluding Bausch + Lomb, delivered another solid quarter, marking fourteen consecutive quarters of year-over-year Revenue and Adjusted EBITDA growth.

news source

PRNewsWire • Oct 28, 2026

news preview

Bausch Health (BHC) Surpasses Q3 Earnings and Revenue Estimates

Bausch Health (BHC) came out with quarterly earnings of $1.77 per share, beating the Zacks Consensus Estimate of $1.08 per share. This compares to earnings of $1.16 per share a year ago.

news source

Zacks Investment Research • Oct 29, 2026

news preview

Bausch (BHC) Reports Q3 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Bausch (BHC) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

news source

Zacks Investment Research • Oct 29, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Bausch Health Companies Inc.

Open an M1 investment account to buy and sell Bausch Health Companies Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in BHC on M1